This paper addresses an important question regarding the characteristics and quality of trials that are not made available for IPD meta-analysis. This is a large comparison of IPD metaanalyses, albeit from one centre and only for oncology trials looking at survival.
grammar needs to be reviewed in places and the paper could be more succinct to make the key message clear.
The authors could also consider discussing the finding that the risk of bias in the IPD-available studies was also not reported clearly for a large proportion of trials.
REVIEWER
Hal Stern University of California, Irvine REVIEW RETURNED 13-Feb-2018
GENERAL COMMENTS Review of "Evaluation of selection bias associated to missing trials data in 18 individual-patient data-meta-analyses of randomized trials in oncology"
The authors use a unique set of data generated during a series of meta-analyses of randomized trials in oncology to study and compare the characteristics of trials with/without individual patient data. This is an interesting scientific question and the results suggest substantial (and important) differences between the two types of trials. This has important implications for meta-analyses.
My view of the manuscript is generally positive but I do have some concerns.
Major concerns:
Title -I find the paper interesting but the title and abstract are not clear. The fact that there are 18 meta-analyses does not seem relevant so I'd drop that from the title. The main focus seems to be on comparing trials with IP data and those without. This should be made clearer in the title, perhaps "Impact of Missing Individual-Patient Data in Meta-Analysis of Randomized Trials in Oncology" or something like that.
Abstract -The abstract is also confusing for me. The objective suggests comparing trial characteristics of IPD and non-IPD studies in a set of IPD-meta-analyses. But how do you have non-IPD studies in an IPD meta-analysis? The design paragraph should also be clearer about what you are doing.
Cochrane risk of bias -It would be valuable to provide more information about the Cochrane risk of bias measure. How do these work? Who is making the judgements regarding study quality and risk of bias?
Data -The heading of Table 1 suggests that some trials are included in more than one of the meta-analyses. If so, how are these treated? Do the trials appear once in Table 1 or more than once.
Trial quality studies -For the trial quality studies you used a set of matched controls. Can you describe this approach more completely. What factors were used to determine the pool of eligible matches? Why did you believe that matching was important here? Table 2 -This table gives the results on trial quality using the matched controls. Matching was done within strata … do the findings of Table 2 hold across strata?
Exclusions -The discussion on page 14 talks about excluding 11 IPD-unavailable RCTs considered at high risk of bias. You don't talk about studies with high risk of bias in the IPD-available pool. Are you excluding these as well?
Minor concerns:
Page 8, line 38 -Should this be p < .10?
Page 17, 5 th line of text -Is "commune" a typo? Is it "common".
VERSION 1 -AUTHOR RESPONSE Reviewer: 1 Reviewer Name: François GUEYFFIER Institution and Country: Claude Bernard Lyon 1 University -Lyon University, France Competing Interests: None declared. I share common interest for meta-analyses on individual patient data with JP Pignon, and related to it we contribute together to works from the ad hoc group from Cochrane Collaboration. However, we never discussed about the presented work and I did not contribute to it at all. This is a really excellent and useful systematic review, allowing to document the characteristics of unavailable trials for IPDMA, compared to those available. Authors used a somewhat extraordinary set of IPDMAs, available in their MA unit, devoted to oncology. The characteristics of unavailable trials are not surprising, and well discussed, but this report is the first one to address this important question. One of the reason is that not much teams have access to such important RCTs IPD data base. The senior author tells the reader that further data could be available on request. His discussion advocates the systematic availability of IPD from all RCTs, through user-friendly systems. It is difficult not to ask him directly whether he would accept to put the data supporting the paper available on the net, and all the questions around (need for trialists agreement, discussion related to the authorship of the subsequent works, control of these further analyses and the related contracts, etc.).
Because this will need agreement of the trialists, we could only provide further information available in the public domain. We then will provide on request the following information: the list of trial references without IPD and the one from those with IPD used for the evaluation of trial quality; the list of trial references for which HR extraction was possible as well as a table with the value of the corresponding HR and their 95% confidence interval. The HR of the trials with IPD could be found in the publication of the corresponding meta-analysis. The table that describes the quality of each trial publication will be also available on request.
The results will be important to help trialists in getting better SOP, helping them to contribute to IPDMA. The conclusions are clear and easy to share: as RCTs must be systematically registered, their IPD must be systematically available so as to prevent publication, selection and other types of biases in systematic reviews, which are already the most important source of information regarding evidence to guide clinical care.
Reviewer: 2 Reviewer Name: Jamilla Hussain Institution and Country: University of Hull, UK Competing Interests: None declared This paper addresses an important question regarding the characteristics and quality of trials that are not made available for IPD meta-analysis. This is a large comparison of IPD meta-analyses, albeit from one centre and only for oncology trials looking at survival.
The paper and abstract, however, could be made much clearer. The grammar needs to be reviewed in places and the paper could be more succinct to make the key message clear. see answer to the editor The authors could also consider discussing the finding that the risk of bias in the IPD-available studies was also not reported clearly for a large proportion of trials.
 The discussion includes now the two following sentences: "Many trials in our sample, including IPD-available trials, did not report sufficient information to evaluate the risk of bias properly, as shown previously by other.": "What we do not know is whether lack of clarity in the report reflects poorer methodological quality of the trial.".
Reviewer: 3 Reviewer Name: Hal Stern Institution and Country: University of California, Irvine, USA Competing Interests: None declared Review of "Evaluation of selection bias associated to missing trials data in 18 individual-patient datameta-analyses of randomized trials in oncology" The authors use a unique set of data generated during a series of meta-analyses of randomized trials in oncology to study and compare the characteristics of trials with/without individual patient data. This is an interesting scientific question and the results suggest substantial (and important) differences between the two types of trials. This has important implications for meta-analyses. My view of the manuscript is generally positive but I do have some concerns.
Major concerns:
Title -I find the paper interesting but the title and abstract are not clear. The fact that there are 18 meta-analyses does not seem relevant so I'd drop that from the title.
The main focus seems to be on comparing trials with IP data and those without. This should be made clearer in the title, perhaps "Impact of Missing Individual-Patient Data in Meta-Analysis of Randomized Trials in Oncology" or something like that.
 We modified the title as suggested by you and the editor (see above), but we prefer to maintain the mention of 18 meta-analyses as it is an important and rare sample as mentioned by the first reviewers. We think that it is also important to specify that all the meta-analyses were performed by the same group.
Abstract -The abstract is also confusing for me. The objective suggests comparing trial characteristics of IPD and non-IPD studies in a set of IPD-meta-analyses. But how do you have non-IPD studies in an IPD meta-analysis? The design paragraph should also be clearer about what you are doing. Cochrane risk of bias -It would be valuable to provide more information about the Cochrane risk of bias measure. How do these work? Who is making the judgements regarding study quality and risk of bias?
 For a given meta-analysis, a set of RCTs eligible was identified when the meta-analysis was performed. For some of those RCTs, IPD were not available. IPD meta-analysis was performed on those with IPD available and without major bias after IPD checking. We compare in this study the non-IPD RCTs to the IPD RCTs. All IPD RCTs were included in the table 1 and corresponding paragraph in the results section. For the other analyses, the IPD-available RCTs excluded from published MAs because of high risk of bias detected when checking the corresponding IPD, were excluded.  Cochrane risk of bias tool is currently used in meta-analysis and the reference 10 describes in detail this tool and how to use it. It is a scale with 7 items with 3 levels (low risk, high risk, unclear risk). The item on reporting bias and other sources of bias were not used, the first one because we were interested only on overall survival and the second because of it was considered as too difficult to assess and of limited use in our setting. To compute an overall quality score by trials is discouraged by Cochrane Collaboration. In our study, we considered an RCT at high risk of bias if one of its items was at high risk of bias as mentioned in the method section. The following sentence was added in the section data collection after the sentence "Two blind investigators extracted data from the selected publications for both IPD-unavailable and the sample of IPD-available RCTs to evaluate RoB using the Cochrane tool [10] ." " Five dimensions were studied and graded as low risk, high risk or unclear: random sequence generation, allocation concealment, blinding of personnel and participants, blinding of outcome assessment, and incomplete outcome data."  Abstract was modified to be clearer.  Quality evaluation was done by two blinded co-authors and discussed with a third one in case of disagreement. We added/modified two sentences in the paper to clarify this issue "Two blind investigators extracted data from the selected publications for both IPD-unavailable and the sample of IPD-available RCTs to evaluate RoB using the Cochrane tool. …..Disagreements were resolved by discussion with a third investigator." and add in the abstract "Two blinded investigators evaluated the RoB for these trials."
Data -The heading of Table 1 suggests that some trials are included in more than one of the metaanalyses. If so, how are these treated? Do the trials appear once in Table 1 or more than once.
 Each trial appears only once in table 1, even if it was eligible for more than one meta-analysis. We added "Some trials were included in more than one MA, but they were counted only once in the table." in the table legend.
Trial quality studies -For the trial quality studies you used a set of matched controls. Can you describe this approach more completely. What factors were used to determine the pool of eligible matches? Why did you believe that matching was important here?
 We limited our selection to full text in English because abstracts usually contain insufficient information to evaluate risk of bias, and because we speak only French and English. We selected all IPD-unavailable RCTs reported as full text in English. As mentioned in the methods section, a sample of IPD-available RCTs, reported as full text in English, was randomly paired with unavailable IPD trials using two factors: -The first inclusion period (before 1997/ 1997 and after) -The meta-analysis which included them,  We think matching on the period was really important since recommendations for reporting evolved with time (first CONSORT Statement in 1996). Matching on MA was performed as inhabits for reporting may vary from a specialty to another. Pairing on this factor may be less important than pairing on period. The corresponding results section was rewritten to make it clearer. Table 2 -This table gives the results on trial quality using the matched controls. Matching was done within strata … do the findings of Table 2 hold across strata?
The overall number of RCTs in this analysis is 73 and the number of strata 12. Then it may be difficult to obtain meaningful results from within strata analysis.
 In the IPD-available pool, the analysis is based on the published results of each meta-analysis. RCTs considered as high risk of bias based on the checking of the IPD were excluded from the corresponding meta-analysis. Then, the included IPD-available RCTs with high risk of bias based on their publication were not considered as such after review of the IPD, completed when available by the review of the protocol. It should be noticed that none of the trials from the 46 IPD-available RCTs in the 2 was at high risk of bias concerning the two randomization items and 10 of them were at high risk of bias concerning incomplete outcome data. As you policy is to request data for postrandomization exclusion patient to perform intent-to-treat analysis and update of the follow-up, a bias suspected in the publication will not exist anymore most of the time in the database used for the metaanalysis. This is a revision of a paper describing a study that compared characteristics (including results) of trials for which individualpatient data was available with trials for which such data was not available. I find the paper to be much improved. There are still a few sections that are not clear.
Comments:
Title -Thank you for changing the title. I believe this is much improved.
Abstract -The abstract is improved. The design paragraph however remains unclear. I'm not sure of the distinction between RCT publications and MA publications. Is this relevant to the reader? Also, I'm not sure it is appropriate to characterize the risk of bias analysis as being done for a "random sample" of RCTs, perhaps just a subset of the studies. Finally, "two blind investigators" should be explained more clearly, perhaps "two investigators blinded to whether IPD was available or not"? (Assuming that's correct) Page 13 -It may be formatting issue but this page seems to be missing the words " Table 1 " at the start of the paragraph.
Page 13, middle -The comparison of reported quality should be made clearer. To start you should mention why you are focused on just 27 IPD-unavailable RCTs. Also, you should spell out that you have 2:1 matching for 19 of the IPD-unavailable trials and 1:1 matching for the other 8. Finally the language around "risk of bias" is confusing to me. What do you mean by a "low risk of bias for random sequence generation"? Should this be referring to "risk of bias due to random sequence generation"? Should it be "risk of bias due to failure to use random sequence generation"? I still think you need more discussion of your use of the Cochrane risk of bias tool.
Page 15, bottom -The discussion of the treatment effect comparison ends with a statement about the impact of excluding 11 IPD-unavailable RCTs considered at high risk of bias. But aren't there also IPD-available TCTs at high risk of bias, and if so shouldn't the sensitivity analysis also exclude these?
VERSION 2 -AUTHOR RESPONSE
Review of "Impact of Missing Individual-Patient Data on 18 Meta-Analyses of Randomized Trials in Oncology: Gustave-Roussy experience" This is a revision of a paper describing a study that compared characteristics (including results) of trials for which individual-patient data was available with trials for which such data was not available. I find the paper to be much improved. There are still a few sections that are not clear.
Comments:
Title -Thank you for changing the title. I believe this is much improved. You are welcome Abstract -The abstract is improved. The design paragraph however remains unclear. I'm not sure of the distinction between RCT publications and MA publications. Is this relevant to the reader? Also, I'm not sure it is appropriate to characterize the risk of bias analysis as being done for a "random sample" of RCTs, perhaps just a subset of the studies. Finally, "two blind investigators" should be explained more clearly, perhaps "two investigators blinded to whether IPD was available or not"? (Assuming that's correct) a) Concerning the source of data, the abstract is a summary of the data collection section in the material and methods. For trial characteristics, the source of data was: -IPD-MA publication for IPD-available RCTs supplemented by the RCT publications and/or our archives when necessary. -RCT publication for IPD-unavailable RCTs For HR, we used IPD-MA publication for the IPD-available RCTs and RCT publication for IPDunavailable RCTs (last paragraph of the data collection section). To mention that the source of HR for IPD-available RCT is IPD-MA publication is important. In the IPD-MA, the survival data is based on updated data with often updated follow-up. And in order to follow the intent-to-treat principle, we recovered data of patients excluded after randomization. For those reasons, the HR in the IPD-MA publication may be different from the HR in the RCT publication.
We modified the first paragraph of the data collection section as follow: "For every eligible RCT, we collected the following data from the available publications: number of randomized patients, date of first patient randomized, date of publication, countries involved, type of publication (e.g., conference abstract), nature of funding, whether the RCT was multicenter or not, and whether it was international or not. This information was extracted from RCT publications for IPDunavailable RCTs and from IPD-MA publications for RCTs with IPD supplemented by the RCT publications and/or our archives if necessary."
We simplified the corresponding sentence in the abstract as follow: "Trial characteristics, risk of bias (RoB), and hazard ratios (HR) for overall survival were extracted from and IPD-MA publications and/or RCTs publications." b) As suggested we changed "random sample" for "subset" as the random selection process was only for a part of the selection for IPD-unavailable RCT (see below for more detail).
c) The two investigators were blinded to whether IPD was available or not and then we modified as suggested the abstract and the text accordingly.
Page 7, lines 20-39 -This paragraph is unclear. It seems as though the starting point was the IPDunavailable trials for which you could get enough methodological information. Is that true? If so, why not say that. Then it would be nice to say why a 2:1 match? Why not all of the IPD-available trials (too costly?)? Here too you mention "blind investigators" but should explain more clearly what information they were blinded about. We aim to study publication-based risk of bias in IPD-unavailable RCTs and to compare the results with a sample of IPD-available RCTs matched on the meta-analysis and the period when RCTs were performed using the Cochrane risk of bias tool in both groups of RCTs publications. The first step was to select the full paper in English in both groups: 27 out of 60 IPD-unavailable RCTs and 232 out of 289 IPD-available RCTs were selected at this step. The 27 IPD-unavailable RCTs belonged to 11 meta-analyses and 12 strata (one time period for 10 meta-analyses, and 2 for one meta-analysis) with one to 8 RCTs by strata. The number of IPD-available RCTs belonging to the 12 strata was 151 with 1 to 67 RCTs by strata, which was expected due to the large variation of the number of RCTs by meta-analysis. For 4 strata, all IPD-available RCTs were included: 3 strata (8 IPD-unavailable RCTs) with 1:1 ratio and one stratum with 1:2 ratio (2 IPD-unavailable RCTs). Random selection was performed for the 8 remaining strata with 1:2 ratio (17 IPD-unavailable RCTs). We did not review all the 151 trials because of time constraints, but only 46 of them. We rewrote the corresponding paragraph to give more detail on the selection process which now read:
"To assess the risk of bias in IPD-unavailable RCTs and compare it with the risk in IPD-available RCTs, we first selected RCTs reported in English as full text articles [30] and excluded conference abstracts and unpublished RCTs because methodological information was insufficient most of the time. [31, 32] Second, IPD-available RCT publication(s) were selected to match with IPD-unavailable RCT publication on MA to which they belonged and the period when the RCT was performed based on the date of randomization of the first patient (before 1997/ 1997 and after). If more than 2 IPDavailable RCTs by IPD-unavailable RCT was available in the strata defined by the two above criteria, we used the Excel ALEA function to randomly select publication of two IPD-available RCTs by IPDunavailable RCT publication."
We added the following sentence: "The number of IPD-available RCT publications selected was limited because of time constraints." See above concerning blinding Page 8, lines 30-35 -Last sentence of this paragraph (beginning "Since potentially biased RCTs…") is unclear. I do not understand what is being described. This paragraph is about the sensitivity analysis of the HR of treatment effect comparison between IPD-available RCTs and IPD-unavailable RCTs. The HR of the IPD-available RCTs group was extracted from our IPD-MA publication. And in our IPD-MA publication, IPD-available RCTs with high risk of bias were excluded. But all IPD-unavailable RCTs (whatever the risk of bias) were used to estimate the HR of the IPD-available RCTs group. This sensitivity analysis was performed in order to compare HRs in IPD-available RCTs and IPDunavailable RCTs groups after exclusion of high risk of bias RCTs in both groups.
"potentially biased RCTs" was changed in "RCTs with high risk of bias" and "of the IPD-available RCTs" was added after "global treatment effect".
Page 13 -It may be formatting issue but this page seems to be missing the words "Table 1" at the start of the paragraph. Thank you, we added Table 1 at the beginning of the sentence. Page 13, middle -The comparison of reported quality should be made clearer. To start you should mention why you are focused on just 27 IPD-unavailable RCTs. Also, you should spell out that you have 2:1 matching for 19 of the IPD-unavailable trials and 1:1 matching for the other 8. Finally the language around "risk of bias" is confusing to me. What do you mean by a "low risk of bias for random sequence generation"? Should this be referring to "risk of bias due to random sequence generation"? Should it be "risk of bias due to failure to use random sequence generation"? I still think you need more discussion of your use of the Cochrane risk of bias tool.
